Pacanalotamab

Pacanalotamab (50 μg/kg/day; i.v. or s.c.; for 18 days) exhibits anti-tumor activity in mouse NCI-H929 xenograft model^[1].
Pacanalotamab (5 μg/kg/day; i.v. or s.c.) significant prolongs survival of mouse in mouse orthotopic L-363 xenograft model^[1].
Pacanalotamab (135 μg/kg/day for i.v. or 405 μg/kg/day for s.c.; up to 28 days) is well tolerated, and it decreases plasma cells in the bone marrow in macaque in toxicity studies^[1].